PHASE II
Using OCZ103-OS in patients with metastatic colorectal cancer undergoing second-line treatment
Completed enrollment:
48 participants in Québec
Study in progress
Clinical program
Oncozyme Pharma is currently evaluating OCZ103-OS in
a phase II clinical study in metastatic colorectal cancer patients
and in a phase IIa clinical study in non-small cell lung cancer
(NSCLC) patients.
Click on any study to learn more.
PHASE IIa
Using OCZ103-OS in combination with platinum-gemcitabine based doublet first-line therapy in patients with stage IV NSCLC.
Completed enrollment:
25 participants in Poland
Study in progress
PHASE I/II
Using OCZ103-OS in patients with metastatic colorectal cancer undergoing second-line or third-line treatment.
Completed enrollment:
25 participants
Completed study
PHASE I/II
Using OCZ103-OS in patients with locally advanced or metastatic pancreatic cancer undergoing standard therapy.
Completed enrollment:
10 participants
Study in progress